Cadwalader Advises HealthCare Royalty Partners in $150 Million Royalty Agreement with Karyopharm Therapeutics

October 15, 2019

Cadwalader advised HealthCare Royalty Partners in connection with a revenue interest financing transaction with Karyopharm Therapeutics for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), Karyopharm’s oral SINE compound that is currently marketed in the United States for the treatment of patients with heavily pretreated multiple myeloma.

The Cadwalader team was led by partner Ira Schacter and included Joo Kim, Steve Lenkowsky and Solomon Brown.

COVID-19 Resource Center

  • Access our insights on the impact of COVID-19 to help you navigate this unprecedented environment.

CadwaladerSpotlight

Making a Mark on Our Communities:

Pro Bono Report 2019

To assist individuals in working from home during the coronavirus social-distancing period, Cadwalader is providing clients and friends free access to our legal research platform, the Cadwalader Cabinet.